Empagliflozin Promises to Bridge the Gap Between Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, and Cardiovascular Disease

Przeglad Gastroenterologiczny - Poland
doi 10.5114/pg.2018.79815
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: Importance of Glycemic Control

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2017English

Metabolic Tandem Targets: Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Medical Council
2017English

Non-Alcoholic Fatty Liver Disease, Cryptogenic Cirrhosis and Type-2 Diabetes Mellitus: How Are They Related?!

Advanced Research in Gastroenterology & Hepatology
2017English

Non-Alcoholic Fatty Liver Disease and Disease Mongering

American Journal of Medicine
Medicine
2019English

Myocardium Remodeling in Patients With Type 2 Diabetes Mellitus Combined With Non-Alcoholic Fatty Liver Disease

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
2016English

Relationship Between Non-Alcoholic Fatty Liver Disease and Thyroid Dysfunction

Internal Medicine
Internal MedicineMedicine
2016English

Lean Non-Alcoholic Fatty Liver Disease: Do Not Forget Diabetes

Archives of Medical Science - Atherosclerotic Diseases
2019English

Cardiovascular Risk Factors in Patients With Non Alcoholic Fatty Liver Disease

Journal of Evolution of Medical and Dental sciences
2013English

Serum Leptin in Non-Alcoholic Fatty Liver Disease: Ambiguous Clinical Implications Concerning Cardiovascular Disease

Clinical and molecular hepatology
MedicineHepatologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy